成大生物(688739.SH):擬投14.02億元建設生物技術產品研發生產基地項目
格隆匯3月23日丨成大生物(688739.SH)公佈,為滿足公司在研項目產業化需求,結合公司實際情況,公司擬投入約14.02億元(最終項目投資總額以實際投資為準)自有資金投資建設生物技術產品研發生產基地項目。
項目計劃分兩期建設,項目一期工程包括重組十五價人乳頭瘤病毒疫苗(大腸埃希菌)(簡稱“15價HPV疫苗”)生產車間、研發中心、質量中心、庫房以及配套公用設施等,項目二期工程包括生物製品標準化廠房,為公司在研項目商業化提供產能儲備。項目建成後,將為公司在研項目按計劃實施提供基礎保障,進一步提高公司商業化能力,增強公司的綜合競爭力。
項目建設期週期為48個月,項目總建築面積共計約14.05萬平方米。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.